These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
402 related articles for article (PubMed ID: 16449807)
1. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies. Diener HC; Cerebrovasc Dis; 2006; 21(4):279-93. PubMed ID: 16449807 [TBL] [Abstract][Full Text] [Related]
2. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Flaker GC; Gruber M; Connolly SJ; Goldman S; Chaparro S; Vahanian A; Halinen MO; Horrow J; Halperin JL; Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169 [TBL] [Abstract][Full Text] [Related]
3. Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials. Albers GW; Am J Manag Care; 2004 Dec; 10(14 Suppl):S462-9; discussion S469-73. PubMed ID: 15696910 [TBL] [Abstract][Full Text] [Related]
5. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Halperin JL; Am Heart J; 2003 Sep; 146(3):431-8. PubMed ID: 12947359 [TBL] [Abstract][Full Text] [Related]
6. Prevention of stroke in patients with atrial fibrillation. Olsson SB; Halperin JL Semin Vasc Med; 2005 Aug; 5(3):285-92. PubMed ID: 16123916 [TBL] [Abstract][Full Text] [Related]
7. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding. Douketis JD; Arneklev K; Goldhaber SZ; Spandorfer J; Halperin F; Horrow J Arch Intern Med; 2006 Apr; 166(8):853-9. PubMed ID: 16636210 [TBL] [Abstract][Full Text] [Related]
8. Trials and tribulations of non-inferiority: the ximelagatran experience. Kaul S; Diamond GA; Weintraub WS J Am Coll Cardiol; 2005 Dec; 46(11):1986-95. PubMed ID: 16325029 [TBL] [Abstract][Full Text] [Related]
9. Direct thrombin inhibition and stroke prevention in elderly patients with atrial fibrillation: experience from the SPORTIF III and V Trials. Ford GA; Choy AM; Deedwania P; Karalis DG; Lindholm CJ; Pluta W; Frison L; Olsson SB; Stroke; 2007 Nov; 38(11):2965-71. PubMed ID: 17885258 [TBL] [Abstract][Full Text] [Related]
10. [SPORTIF III and V trials: a major breakthrough for long-term oral anticoagulation]. Kulbertus H Rev Med Liege; 2003 Dec; 58(12):770-3. PubMed ID: 14978854 [TBL] [Abstract][Full Text] [Related]
11. Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials. Akins PT; Feldman HA; Zoble RG; Newman D; Spitzer SG; Diener HC; Albers GW Stroke; 2007 Mar; 38(3):874-80. PubMed ID: 17255547 [TBL] [Abstract][Full Text] [Related]
12. Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation. Halperin JL J Am Coll Cardiol; 2005 Jan; 45(1):1-9. PubMed ID: 15629364 [TBL] [Abstract][Full Text] [Related]
13. Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials. Gomberg-Maitland M; Wenger NK; Feyzi J; Lengyel M; Volgman AS; Petersen P; Frison L; Halperin JL Eur Heart J; 2006 Aug; 27(16):1947-53. PubMed ID: 16774980 [TBL] [Abstract][Full Text] [Related]
14. Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor. Halperin JL Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):163-74. PubMed ID: 15151465 [TBL] [Abstract][Full Text] [Related]
15. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. Petersen P; Grind M; Adler J; J Am Coll Cardiol; 2003 May; 41(9):1445-51. PubMed ID: 12742279 [TBL] [Abstract][Full Text] [Related]
16. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Olsson SB; Lancet; 2003 Nov; 362(9397):1691-8. PubMed ID: 14643116 [TBL] [Abstract][Full Text] [Related]
17. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. Lip GY; Frison L; Halperin JL; Lane DA J Am Coll Cardiol; 2011 Jan; 57(2):173-80. PubMed ID: 21111555 [TBL] [Abstract][Full Text] [Related]
18. Will direct thrombin inhibitors replace warfarin for preventing embolic events in atrial fibrillation? Reiffel JA Curr Opin Cardiol; 2004 Jan; 19(1):58-63. PubMed ID: 14688636 [TBL] [Abstract][Full Text] [Related]
20. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?]. Selçuk H; Selçuk MT; Maden O Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]